Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma
5 Visualizzazioni
• 08/09/23
0
0
Incorporare
administrator
Iscritti
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti